- Home
- AUROW vs TGTX Comparison
AUROW vs TGTX Comparison
Compare AUROW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUROW
- TGTX
- Stock Information
- Founded
- AUROW 2017
- TGTX 1993
- Country
- AUROW United States
- TGTX United States
- Employees
- AUROW 1800
- TGTX N/A
- Industry
- AUROW EDP Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- AUROW Technology
- TGTX Health Care
- Exchange
- AUROW Nasdaq
- TGTX Nasdaq
- Market Cap
- AUROW N/A
- TGTX 5.5B
- IPO Year
- AUROW N/A
- TGTX 1995
- Fundamental
- Price
- AUROW $0.50
- TGTX $34.70
- Analyst Decision
- AUROW
- TGTX Strong Buy
- Analyst Count
- AUROW 0
- TGTX 6
- Target Price
- AUROW N/A
- TGTX $47.50
- AVG Volume (30 Days)
- AUROW 137.0K
- TGTX 1.7M
- Earning Date
- AUROW 04-30-2025
- TGTX 11-03-2025
- Dividend Yield
- AUROW N/A
- TGTX N/A
- EPS Growth
- AUROW N/A
- TGTX N/A
- EPS
- AUROW N/A
- TGTX 0.36
- Revenue
- AUROW N/A
- TGTX $454,069,000.00
- Revenue This Year
- AUROW N/A
- TGTX $82.22
- Revenue Next Year
- AUROW N/A
- TGTX $47.76
- P/E Ratio
- AUROW N/A
- TGTX $96.10
- Revenue Growth
- AUROW N/A
- TGTX 30.96
- 52 Week Low
- AUROW $2.09
- TGTX $22.61
- 52 Week High
- AUROW $3.00
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- AUROW 38.48
- TGTX 56.00
- Support Level
- AUROW $0.55
- TGTX $33.10
- Resistance Level
- AUROW $0.65
- TGTX $35.64
- Average True Range (ATR)
- AUROW 0.05
- TGTX 1.21
- MACD
- AUROW -0.00
- TGTX -0.14
- Stochastic Oscillator
- AUROW 18.14
- TGTX 36.78
About AUROW Aurora Innovation Inc. Warrant
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.